The Big Debate: The 21st Century Cures Act

18 January 2016

The 21st Century Cures Act was passed by the US House of Representatives in July 2015 and is sparking debate in the medical community. The Act aims to get cures from research to medical practice faster and covers everything from discovery to research funding, drug development, Food and Drug Administration approval, and Medicare, writes Dr Nicola Davies in her regular exclusive article for The Pharma Letter.

However, the House Commerce and Energy Committee observes that advances in genetics will require further regulatory reforms and funding before new discoveries can be used in treatment. In addition, there are a number of other concerns.

Is “Accelerated” FDA approval dangerous?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK